Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

Inclusion Criteria

Patients must be 18 years of age or older at the time of enrollment.
Patients must be diagnosed with active and measurable relapsed/refractory multiple myeloma.
Patients must have failed at least 3 prior lines of therapy which must have included an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 drug or biologic. Failure of treatment and measurable myeloma disease are defined as per 2016 IMWG criteria.
Patients must have clinical performance status of ECOG 0-2.
Patients must have adequate vital organ function as defined by:
Hemoglobin ≥8 g/dL
Absolute neutrophil count > 1000/ mm3
Platelets > 50,000/mm3
ALT/AST levels lower than 3-fold of normal
Creatinine clearance ≥45 mL/min/1.73 m2
Normal cardiac and pulmonary function
No thromboembolic events in the past 3 months
No heparin allergy or active infection

Exclusion Criteria

Patients who have any active and uncontrolled infection.
Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine or systemic steroids above 40 mg/day prednisone equivalent).
Patients who have active central nervous system disease.